Equity Overview
Price & Market Data
Price: $1.97
Daily Change: -$0.05 / 2.54%
Daily Range: $1.93 - $2.05
Market Cap: $7,489,162
Daily Volume: 44,731
Performance Metrics
1 Week: 19.39%
1 Month: -18.93%
3 Months: -19.26%
6 Months: -12.83%
1 Year: -78.54%
YTD: 8.24%
Company Details
Employees: 7
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.